Topiglan: MacroChem

Current Opinion in Investigational Drugs

Volumn 3, Issue 4, 2002, Pages 602-606

  McMahon, Chris G ^a  

^a Australian Centre for Sexual Health   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; PROSTAGLANDIN E1; SKIN ABSORPTION ENHANCER EXCIPIENT; UNCLASSIFIED DRUG; PHARMACEUTICAL VEHICLES AND ADDITIVES; VASODILATOR AGENT;

CLINICAL TRIAL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; ERYTHEMA; HUMAN; IMPOTENCE; NONHUMAN; PATENT; REVIEW; SKIN ABSORPTION; SKIN IRRITATION; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; ANIMAL; GEL; INTRADERMAL DRUG ADMINISTRATION; MALE; METABOLISM;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, CUTANEOUS; ALPROSTADIL; ANIMAL; CLINICAL TRIALS; GELS; HUMAN; IMPOTENCE; MALE; VASODILATOR AGENTS; ANIMALS; HUMANS;

EID: 0035988857     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Intracavernous injection of vasoactive drugs in the rabbit
2. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease
3. Ongoing clinical trials with MacroChem's gel for erectile dysfunction, Topiglan, confirming earlier results
4. Clinical trial results presented at International Society for Impotence Research further confirm and extend efficacy and safety profile of Topiglan
5. US Patent Office issues allowance of all claims in Topiglan patent application
6. MacroChem announces successful results of new safety trials on Topiglan, its topical erectile dysfunction drug
7. Macrochem awarded US patent on Topiglan and announces filing of foreign patents on its antifungal compositions
8. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction
9. MacroChem's topical drug for erectile dysfunction passes critical test: Partners of users display no systemic effects during or after intercourse
10. MacroChem announces Topiglan patent filings in Europe, Asia, Latin America
11. MacroChem's drug-absorption enhancer passes critical carcinogenicity test
12. Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction
13. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle
14. MacroChem will initiate phase III home trial of its erectile-dysfunction drug, topiglan: Trial will test topical gel in more than 400 patients with ED
15. MacroChem reports major progress on bringing first topical male impotence drug to clinical practice
16. OXIS International names Joseph F Bozman, Jr, Chairman, President and CEO: Announcement follows significant management changes
17. MacroChem announces initiation of open-label continuation phase III study of topical erectile-dysfunction drug 30 clinical sites currently participating in pivotal home trial of novel topical treatment for impotence
18. Urology 'gold journal' publishes successful phase II study of innovative topical drug for erectile dysfunction - Topiglan encouraged erections judged intercourse-competent in almost 6X as many moderate-to-severely impotent men as placebo in office trial by world- leading expert in erectile dysfunction
19. A double blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction
20. Phase III study shows statistically significant improvement in erectile function in patients treated with Topiglan
21. Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model
22. Thermal and spectroscopic characterisation of interactions between 2-n-nonyl-1-3-dioxolane and stratum corneum components
23. Histological characterisation of the skin of the glans penis
24. SEPA-009-safety and efficacy studies of a broad spectrum transdermal enhancer
25. On the metabolism of prostaglandins E1 and E2 in man
26. Prostaglandin 15-hydroxy-dehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin mediated penile erection
27. Pharmacokinetics of vasoactive substances administered into the human corpora cavernosa
28. Circulation parameters during venous and intra-arterial administration of increasing does of prostaglandin E1 in healthy subjects
29. Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1 and saline in primates
30. Penile scarring with intracorporal injection therapy using prostaglandin E1: A risk factor analysis
31. Tolerance of Topiglan, a topical treatment for ED during vaginal intercourse
32. Safety and efficacy of topical prostaglandin gel formulation (Topiglan) in the treatment for erectile dysfunction
33. MacroChem Corp.
34. Inhibitory effects of prostaglandin E1 on responses of rabbit ear artery to nerve stimulation and on release of norepinephrine
35. Biochemistry and pharmacology of prostaglandin E1: Introductory remarks
36. Directory of prostaglandins
37. Actions of PGE1, 15-Keto-PGE1 on vessel tone in vitro
38. The role of alprostadil in the diagnosis and treatment of erectile dysfunction